Table 1. Patent characteristics.
| All patients (N=773) | Patients on ADs (n=203) | Patients on SSRIs (n=125) | ||||
|---|---|---|---|---|---|---|
| Characteristic | No. | % | No. | % | No. | % |
| Age (years) | ||||||
| Median | 60.1 | 59.0 | 59.7 | |||
| IQR | 52-68 | 50.3-67 | 51-67 | |||
| FU duration, months | ||||||
| Median | 54.8 | 58.8 | 62.5 | |||
| IQR | 31.4-85.3 | 33.5-83.2 | 37.7-83.2 | |||
| Race | ||||||
| White | 679 | 91.6 | 183 | 97.3 | 115 | 97.5 |
| Other | 62 | 8.4 | 5 | 2.7 | 3 | 2.5 |
| Stage | ||||||
| I | 78 | 10.2 | 23 | 11.3 | 16 | 12.8 |
| II | 60 | 7.8 | 15 | 7.4 | 10 | 8.0 |
| III | 549 | 71.9 | 147 | 72.4 | 88 | 70.4 |
| IV | 77 | 10.1 | 18 | 8.9 | 11 | 8.8 |
| Residual Disease | ||||||
| Optimal | 492 | 63.7 | 140 | 69.0 | 87 | 69.6 |
| Suboptimal | 281 | 36.4 | 63 | 31.0 | 38 | 30.4 |
| Grade | ||||||
| High | 627 | 81.4 | 173 | 85.2 | 105 | 84.0 |
| Low | 143 | 18.6 | 30 | 14.8 | 20 | 16.0 |
| Histology | ||||||
| Serous | 582 | 75.5 | 155 | 76.4 | 93 | 74.4 |
| Other | 189 | 24.5 | 48 | 23.6 | 32 | 25.6 |
| ADs | 203 | 26.3 | 203 | 100.0 | 125 | 100.0 |
| SSRIs | 125 | 16.2 | 125 | 61.6 | 125 | 100.0 |
| SNRIs | 44 | 5.7 | 44 | 21.7 | 7 | 5.6 |
| TCAs | 24 | 3.1 | 24 | 11.8 | 3 | 2.4 |
| NDRIs | 18 | 2.3 | 18 | 8.9 | 5 | 4.0 |
| SARIs | 11 | 1.4 | 11 | 5.4 | 3 | 2.4 |
| NaSSAs | 9 | 1.2 | 9 | 4.4 | 3 | 2.4 |
Abbreviations: ADs, antidepressants; FU, follow-up; IQR, interquartile range; NaSSAs, noradrenergic and specific serotonergic antidepressants; NDRIs, norepinephrine-dopamine reuptake inhibitors; SARIs, serotonin antagonist-reuptake inhibitors; SNRIs, selective norepinephrine-reuptake inhibitors; SSRIs, selective serotonin-reuptake inhibitors; TCAs, tricyclic antidepressants.